Amgen Inc. (FRA:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 150.44B |
| Revenue (ttm) | 30.66B |
| Net Income (ttm) | 5.97B |
| Shares Out | n/a |
| EPS (ttm) | 11.02 |
| PE Ratio | 25.20 |
| Forward PE | 15.68 |
| Dividend | 8.52 (3.05%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 45 |
| Average Volume | 110 |
| Open | 276.40 |
| Previous Close | 275.05 |
| Day's Range | 275.60 - 279.75 |
| 52-Week Range | 230.00 - 304.75 |
| Beta | n/a |
| RSI | 50.44 |
| Earnings Date | Feb 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Daily Dividend Report: OLP,TJX,AMGN,O,CAT
One Liberty Properties today announced that its Board of Directors declared a quarterly dividend on the Company's common stock of $0.45 per share. The dividend is payable on January 6, 2026 to stockho...
AMGN: Wells Fargo Raises Price Target to $325, Maintains Equal-Weight Rating | AMGN Stock News
AMGN: Wells Fargo Raises Price Target to $325, Maintains Equal-Weight Rating | AMGN Stock News
Amgen: Improving Balance Sheet Is Bringing The Stock Close To Being A "Buy"
Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming patent expirations.
Amgen (AMGN) to Participate in Upcoming Virtual Meeting
Amgen (AMGN) to Participate in Upcoming Virtual Meeting
Amgen raises dividend by ~6%
Amgen raises its quarterly dividend by 5.9% to $2.52/share, boosting its forward yield to 3.21%. See updated yield chart.
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026.
Recent Filing Shows That Rep. David Taylor Sold Over $2K Worth of Amgen Stock
Records from December 5, 2025 indicate that Representative David Taylor of Ohio made a sale of Amgen (NASDAQ: AMGN), valued between $2,002 and $30,000, with the transaction dated December 3, 2025 and...
SCHD, AMGN, BMY, LMT: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Dividend Equity ETF (Symbol: SCHD) where we have detected an...
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen Inc at Evercore ISI Healthcare Conference Transcript
Amgen Inc at Evercore ISI Healthcare Conference Transcript
Amgen Inc at Citi Global Healthcare Conference Transcript
Amgen Inc at Citi Global Healthcare Conference Transcript
Amgen: Stagnation And The IRS Are Coming
Amgen (AMGN) is at risk of long-term stagnation due to an impending patent cliff and limited pipeline catalysts.
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
AMGN Factor-Based Stock Analysis
Below is Validea's guru fundamental report for AMGEN INC (AMGN). Of the 22 guru strategies we follow, AMGN rates highest using our Multi-Factor Investor model based on the published strategy of Pim va...
BMO Capital Raises Price Target for Amgen (AMGN) to $372, Maintains 'Outperform' | AMGN Stock News
BMO Capital Raises Price Target for Amgen (AMGN) to $372, Maintains 'Outperform' | AMGN Stock News
2 Dividend Stocks to Double Up On Right Now
Coca-Cola is showing why it has increased its dividend for 63 consecutive years. Amgen should maintain its strong dividend program despite some patent cliffs.
SCHD: Tops Dividend Competitors On Value, Yield, And Sustainability
SCHD's top holdings, including Merck and Amgen, combine strong profitability, sustainable payout ratios, and attractive valuations. Read why SCHD ETF is a Buy.
Biocon Biologics secures market pathway for Denosumab Biosimilars in Europe following settlement with Amgen
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that it has finalized...
Noteworthy Monday Option Activity: AMGN, NLY, CRM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN), where a total of 16,674 contracts have traded so far, representin...
Is the Market Bullish or Bearish on Amgen Inc?
Amgen Inc's (NYSE: AMGN) short interest as a percent of float has risen 16.82% since its last report. According to exchange reported data, there are now 13.43 million shares sold short , which is 2.5...
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
Dogs Of The Dow Continue Outperforming Broader Market
Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index ret...
Amgen (AMGN) Stock Signal: Is There More Room to the Upside? - 27 November 2025
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?
Hard for Eli Lilly to move significantly higher from here in the short-term: Kessef Capital's Yaffee
Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.